Sat.Jul 23, 2022 - Fri.Jul 29, 2022

article thumbnail

Study: Antibody Levels Decrease Within 3 Months After COVID-19 Booster

Pharmacy Times

The immune responses to the Omicron variant waned substantially with neutralizing antibody levels decreasing 2.4- to 5.3-fold by 3 months after the booster dose.

article thumbnail

Macmillan alliance will provide digital health apps to cancer patients

pharmaphorum

Newly diagnosed cancer patients across the UK will get free access to digital mental health therapies, thanks to a new partnership between Macmillan Cancer Support and Big Health. The alliance, billed as the first of its kind in the UK, means that cancer patients will be able to use Big Health apps like Sleepio and Daylight, which aim to treat insomnia and anxiety using cognitive behavioural therapy (CBT) techniques.

134
134
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Personalizing the Cancer Patient Journey

Pharma Marketing Network

In the first two weeks after a cancer diagnosis, there are likely dozens of doctor’s visits, tests, consultations, and decision points. The patient care team supplies an abundance of information, although sifting through brochures and online resources can be daunting for the patient and their caregiver. Adhering to regulatory guidelines is an important step pharma takes to ensure that promotional medical materials contain balanced information that is accurate and relevant. 1 The marketer’s goal

article thumbnail

Digital Engagement is Only as Good as the First-Party Data It Provides

PharmExec

First-party insights bridge marketing and sales to deliver better HCP experiences.

124
124
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Study: Fourth Dose of COVID-19 Vaccine Provides Protection Against Omicron Variant

Pharmacy Times

A majority of long-term care patients who received a fourth vaccination against COVID-19 were found to have increased protection against the omicron variant.

Vaccines 162
article thumbnail

Philips on designing innovation and cultivating partnerships – part one

pharmaphorum

Sachin Grover, lead of solutions vertical at Philips India, tells me about the company’s innovations during India’s COVID outbreak and how they’ve led to increased healthcare access in the region. There is a vast difference in India’s healthcare system between rural and urban areas, but Philips’ team in the region is working hard to close that gap and improve access to healthcare. “It’s been 75 years since India’s independence.

More Trending

article thumbnail

Human element important for decentralized trial advancement

Outsourcing Pharma

During the Decentralized Trial Technology event, experts from CVS Health, University of Chicago, and ACRP shared insight on what can increase DCT success.

120
120
article thumbnail

COVID-19 Linked with Disruptions to Medication for Opioid Use Disorder

Pharmacy Times

The pandemic saw reductions in the supply of methadone but no disruption to the supply of more easily accessible buprenorphine, though disparities in supply were observed across states.

149
149
article thumbnail

Pfizer takes COVID jab with ‘enhanced’ spike protein into phase 2

pharmaphorum

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants. The vaccine, codenamed BNT162b5, codes for “enhanced” prefusion spike proteins from the original wild-type strain of the virus and the Omicron variant that are designed to increase “the magnitude and breadth of the immune response.” The phase 2 trial will te

Vaccines 122
article thumbnail

Lupus discovery lends clues to the fight against long COVID

PharmaVoice

So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki help lead the way.

119
119
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Do generics producers have what it takes to tackle complex and specialty drugs?

Pharmaceutical Technology

With decreasing margins on the horizon, pharma manufacturers have long shown an interest in specialty generics, which is only expected to rise in the future. Despite this, specialty generics are expected to be the domain of a handful of companies with the necessary manufacturing capabilities and legal backing needed for entering the market. Specialty generics is a term used to refer to generic versions of drugs that are often expensive, complex, or “high touch”—requiring significant involvement

FDA 119
article thumbnail

Illinois Bill Allows Pharmacists to Prescribe HIV Pre-, Post-Exposure Prophylaxis Drugs, Testing

Pharmacy Times

The bill allows pharmacists to dispense and administer drugs, order laboratory tests, and consult patients on HIV pre- and post-exposure drugs.

149
149
article thumbnail

EU proposes new blood, tissues and cells Regulation

European Pharmaceutical Review

The European Commission (EC) has issued a draft proposal for a new EU Regulation on blood, tissues and cells (BTC) to help increase the safety and quality of substances of human origin (SoHO). The Regulation will cover all SoHO (eg, blood, tissues, cells, breast milk and microbiota) except solid organs. A major aim of the proposal is to enhance the protection of recipients of SoHO therapies, as well as donors of SoHO and offspring from medically assisted reproduction.

116
116
article thumbnail

How can the pharma industry navigate issues in the global supply chain to minimise drug shortages?

pharmaphorum

Supply chain shortages have dominated headlines for several months, and the pharma industry has been no exception. While navigating changes has long been a challenge for the industry, the last two years’ events have made supply chain management significantly more difficult. The pandemic effectively shut down supply chain paths overnight, and as a result, pharmaceutical manufacturers have faced delays and bottlenecks, which have caused drug shortages in healthcare systems.

FDA 111
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Embracing digitalization in the pharmaceutical supply chain

Pharmaceutical Technology

The COVID-19 pandemic triggered significant changes to the way healthcare operates. Digitalization is now in full swing as medical care integrates with ICT to take the patient experience to the next level. According to Tom Lenaerts, Head of Global Process Engineering at Datwyler, this transformation will reshape the entire healthcare ecosystem. “There are already opportunities for patients to track their health through smart medical devices sending reports directly to their healthcare provider.

article thumbnail

An Overview of Antimicrobials in Pneumonia Pharmacotherapy

Pharmacy Times

The most common way to detect bacteria and determine the right medication to use is with the gram stain test, which will show whether the bacteria is gram-positive or gram-negative.

145
145
article thumbnail

The earlier the better: New consortium leverages infant screening to accelerate treatment

PharmaVoice

Inozyme Pharma has joined a genomic sequencing program developing a novel rapid test for 388 genetic diseases.

105
105
article thumbnail

CHMP meeting highlights – July 2022

European Pharmaceutical Review

Recommended for approval. Amvuttra * (vutrisiran) was recommended for marketing authorisation as a treatment for adults with hereditary transthyretin-mediated amyloidosis, a rare life-threatening disease that damages multiple nerves across the body. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Celdoxome pegylated liposomal (doxorubicin hydrochloride) for the treatment of metastatic breast cancer, advanced ovaria

Vaccines 105
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Pfizer reports 53% operational growth in Q2 2022 revenues

Pharmaceutical Technology

Pfizer has reported a 53% operational growth in revenues to $27.7bn in the second quarter (Q2) of 2022 compared to $18.9bn in the same quarter last year. The rise in revenues was chiefly driven by robust contributions from Covid-19 therapies Paxlovid and Comirnaty. On an operational basis, the revenues rose by $128m or 1%, excluding Paxlovid and Comirnaty’s contributions.

105
105
article thumbnail

Vitamin B6 Supplements Reduces Anxiety, Depression in New Study

Pharmacy Times

Participants took about 50 times higher than the recommended daily allowance every day for a month, investigators say.

139
139
article thumbnail

Behind Pfizer's new quest to target a 'transformation' in pharma

PharmaVoice

A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

105
105
article thumbnail

Tackling fake pharmaceuticals: an industry united against counterfeit products

European Pharmaceutical Review

While the global trade of fake pharmaceuticals has long been a threat, the COVID-19 pandemic sent the fraudulent market into overdrive. Criminals were able to capitalise on supply chain disruptions, industry regulations being in transition and the urgent global demand for medical products; consequently they thrived. A week before COVID-19 was even declared a pandemic by the World Health Organization (WHO), 1 Interpol’s Operation Pangea XIII seized counterfeit virus interventions 2 worth $14 mill

Packaging 104
article thumbnail

FDA accepts to review ImmunityBio’s BLA for bladder cancer treatment

Pharmaceutical Technology

The Food and Drug Administration (FDA) has acc epted to review ImmunityBio’s Biologics License Application (BLA) for N-803 to treat Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients with or without Ta or T1 disease. A decision from the regulatory agency on approval for the treatment is anticipated on 23 May next year.

FDA 105
article thumbnail

6 Major Trends Boosting the Telemedicine Market in Health Care

Pharmacy Times

The number of medical visits carried out via telehealth grew from 840,000 in 2019 to 52.7 million in 2020.

136
136
article thumbnail

Roche’s fast-growing eye drug Vabysmo set for EU approval

pharmaphorum

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer’s mighty Eylea in the US – and could soon start making inroads against its rival in Europe. Vabysmo (faricimab) has been recommended by the EMA’s human medicines committee as a treatment for neovascular or wet age-related macular degeneration (AMD) and diabetic macular oedema (DME), so could be fully approved and ready to roll out in the next few months, subject to pricin

FDA 99
article thumbnail

Biohybrid microrobots could be effective cancer drug delivery systems

European Pharmaceutical Review

Researchers have constructed biohybrid microrobots, by equipping Escherichia coli bacteria with artificial components, that could one day offer a highly targeted and effective cancer treatment option. The team of scientists from the Physical Intelligence Department at the Max Planck Institute for Intelligent Systems combined robotics with E. coli bacteria to construct their innovative drug delivery system.

article thumbnail

Can a nasal spray tackle agitation in autism?

Pharmaceutical Technology

The rate at which children are being identified with autism spectrum disorder (ASD) has tripled in the past two decades. While the prevalence was 1 in 150 children in 2000, it reached the rate of 1 in 44 in 2018, in the US, according to the Centers for Disease Control and Prevention. Some people with ASD can experience acute agitation and crisis behaviours.

article thumbnail

Oncology Overview: Adagrasib (MRTX849) for Non-Small Cell Lung Cancer

Pharmacy Times

The FDA is evaluating the use of adagrasib (MRTX849) to treat patients with non-small cell lung cancer harboring a KRAS G12C mutation who have previously received at least 1 systemic therapy.

FDA 132
article thumbnail

Personalized data could bring PhysIQ to the forefront of clinical trial evolution

PharmaVoice

The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.

98
article thumbnail

Healthware forms new medical communications division

pharmaphorum

Health innovation and technology specialist Healthware Group has added another element to its business with the launch of a dedicated medical communications and education division. The new unit – dubbed Healthware MedComms – promises to take a fresh approach to medical communications that meets “the always-on, audience-centric, evidence-driven demands of today’s modern clinical environment.” It adds to Healthware’s fast-growing presence in the healthcare communications se

article thumbnail

EMA task force begins review of Veru’s sabizabulin for Covid-19

Pharmaceutical Technology

The Emergency Task Force (ETF) of the European Medicines Agency (EMA) has commenced the review of Veru’s sabizabulin to treat hospitalised Covid-19 patients at increased acute respiratory distress syndrome (ARDS) risk. The review will facilitate the use of the therapy for emergency usage in countries in the European Union (EU). Under this process, the ETF will analyse all available data, including findings from a trial in moderate-to-severe Covid-19 patients admitted to hospital who are at incre

Hospitals 104
article thumbnail

Pharmacists Can Help Manage Patients With Parkinson Disease

Pharmacy Times

They can assess for adherence, identify drug-related problems, monitor pharmacotherapy, and provide education.

132
132
article thumbnail

Woman of the Week: Applied BioMath's Katie Williams

PharmaVoice

The 2022 president of Women in Bio is equal parts math and gender parity evangelist.

98